Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Results br Discussion secretase mediated proteolysis of
2021-10-15

Results Discussion γ-secretase-mediated proteolysis of integral membrane proteins is required for diverse biological processes (Lal and Caplan, 2011). One γ-secretase target of particular interest is Notch, as recent work has shown Notch activity to be increased in obesity and associated metab
-
Introduction G quadruplexes are therapeutically important no
2021-10-15

Introduction G-quadruplexes are therapeutically important non-canonical nucleic knowledge structures that are formed by a planar assembly of four guanines, termed G-tetrads (Fig. 1), in the guanine rich regions of genome [[1], [2], [3]]. As it is getting increasingly established, several life form
-
br Competing interests br Authors contributions br Transpare
2021-10-15

Competing interests Authors contributions Transparency document Introduction Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which may further progress to liver cirrhosis and liver carcinoma
-
Hydantoin in region F bridging
2021-10-15

Hydantoin in region F bridging the phenoxybenzene and benzimidazole moieties was replaced by cyclic building blocks, diketopiperazine (25) and imidazolidinone (26), and linear bonds, amide (27) and urea (28). Analogs 25–28 possessing the linkers other than hydantoin were not tolerated in LBD of FXR,
-
On the contrary the benzhydrol series showed
2021-10-15

On the contrary, the benzhydrol series showed modest activity with EC of two digit micromole. The bulkiness of the Methscopolamine tail may be the reason for the low activity. Interestingly, introduction of H-bonding groups, such as OMe in and CF in , slightly improved the activity compared to the
-
This hypothesis is in line with our phylogenetic analysis of
2021-10-15

This hypothesis is in line with our phylogenetic analysis of FBPase sequences which revealed that vertebrate FBP2 evolved significantly faster than FBP1 (Fig. 2). An average distance between FBP2 and ancestral vertebrate FBPase was higher than that for FBP1. Moreover, preliminary study on amphibia
-
Last we demonstrate that the
2021-10-15

Last, we demonstrate that the role of EZH2 as a transcriptional activator, with AR being a key target, coexists with its conventional catalytic role in gene repression and plays important oncogenic functions in AR-driven PCa (Figure 7F). Enzymatic EZH2 inhibitors such as EPZ and GSK126, although eff
-
The exocytosis promotion is triggered upon the binding of Ca
2021-10-15

The Parathyroid Hormone (1-34), bovine receptor promotion is triggered upon the binding of Ca2+ to the C2 domains of two key protein groups, i.e. complexin and certain synaptogamins (Lai et al., 2017; Rizo and Xu, 2015). The first step of the vesicle fusion is the priming of the secretory vesicles,
-
The initial hyperproliferation phase during crypt regenerati
2021-10-15

The initial hyperproliferation phase during crypt regeneration is reminiscent of the effects of Apc loss during tumour initiation and genetic studies show Yap and Taz are also required for adenoma formation in mice [10••, 12•, 13]. Furthermore, Yap activation by Mst1/2 or Sav deletion increases cry
-
br Pharmacological anti aging approaches and the Hippo pathw
2021-10-15

Pharmacological anti-aging approaches and the Hippo pathway Aging and age-related pathologies are the main causes of disabilities and death. As Magalhañes and colleagues suggest, the challenges of developing anti-aging pharmacological therapies may, in part, be due to the complexity of aging mole
-
PDEs a group of metallophosphohydrolases hydrolyze the cycli
2021-10-15

PDEs, a group of metallophosphohydrolases, hydrolyze the 3′,5′-cyclic phosphate group on cyclic nucleotides to a 5′-monophosphate, thereby blocking cyclic AMP (cAMP) or cGMP signaling [8,9]. There are different types of PDE isozymes, with different substrate specificities. PDE5 (specific to cGMP) an
-
Recent studies on detailed biochemical and
2021-10-15

Recent studies on detailed biochemical and structural characterization of plant GSNOR YM 022 mg confirmed their similarities to mammalian homologues [16], [17], [18], [19]. Compared to human GSNOR, plant GSNORs exhibit differences in the composition of the anion-binding pocket, which negatively inf
-
Finally our work showed that
2021-10-15

Finally, our work showed that HAART resulted in significant inter-individual variability among DEGs, which reflected the SKF 83566 hydrobromide in HIV-affected human gene expressions (Fig. 1, Fig. 2, Fig. 3, Fig. 4). These observations also highlighted the importance of determining common as well a
-
br Lysophosphatidylinositol LPI LPI is a
2021-10-15

Lysophosphatidylinositol (LPI) LPI is a subspecies of lysophospholipid consisting of inositol as its head group, one glycerol molecule and one acyl chain (Piñeiro and Falasca, 2012). The biosynthesis of this lipid starts from Phosphatidylinositol (PI) and is catalysed by the enzymes phospholipase
-
The compounds described in this paper were
2021-10-15

The compounds described in this paper were prepared using a modular approach that allowed diversification of R or R at the final step (). Route A involved amide coupling of -butyl 4-(methylamino)piperidine-1-carboxylate with phenyl acetic acids (step a) using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-m
16058 records 555/1071 page Previous Next First page 上5页 551552553554555 下5页 Last page